暗盤前瞻丨康基醫療、海吉亞醫療：同獲高瓴、奧博資本等頂級機構加持，國配認購超20倍
uSMART友信智投6月26日消息，康基醫療、海吉亞醫療今日公佈配售結果，並將於16:15進行暗盤交易。
這兩隻新股同屬港股熱門的醫藥行業，且都有高瓴資本、奧博資本等國際頂級機構作為基石，自然獲得了市場的搶購。
從中簽率來看，兩隻新股的1手中簽率均偏低。
雖然海吉亞醫療甲組中分給1手黨的股份只佔8.5%，但整體來說中簽較容易，1手中簽率8.8%，申購10手的中簽率提升到38%。
而康基醫療甲組分給1手黨的股份佔到16.1%，1手中簽率9%，10手中簽率僅13%，申購20手的中簽率提升到24%，20手之後中簽率提升較明顯。
康基醫療認購人數超過41萬，凍資額將近3095億港元，一舉超越京東，問鼎今年新的“新股雙料王”，其認購人數也接近十年來的人氣王閱文集團的41.8萬。乙組認購人數超過1.5萬，超過沛嘉醫療的約1.2萬，是十年來的最高。
國配認購倍數高達29.05倍，也是近期的最高值了，之前的大熱門沛嘉醫療國配也只有20倍。
從貨源來看，算上國配中超額分配的15%股份，公開發售部分佔43%，7位元基石鎖定35.54%，其他國配投資者只有約21.5%，其中13000股份給了關聯客戶華夏基金、中信證券，佔比不高，40萬股份給了老股東，約佔發售股份的0.15%。
康基醫療上市之初市值為173.8億港元，以下為wind統計的港股醫療器械板塊的估值情況。
海吉亞醫療的各項認購資料稍遜於康基醫療，但也屬於近年來的top級別。國配認購倍數也達到了25倍的罕見數字。
且基石拿貨比例較高，算上超額分配的15%股份後，9位基石持股比例佔到43.41%，高於康基醫療，即其他國配投資者拿到的股份只有13.6%，其中3000股份給了關聯客戶富國資管。
暗盤預報
uSMART友信證券暗盤交易時間：6月26日 16:15~18:30
配售結果 | 海吉亞醫療：1手中簽率8.8%，超30萬人申購，公開認購608.56倍，國配認購25倍
配售結果 | 康基醫療：1手中簽率9%，超41萬人申購，公開認購989.22倍，國配認購29.05倍
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
